Form 8-K

8-K — GILEAD SCIENCES, INC.

Accession: 0000882095-26-000028

Filed: 2026-08-04

Period: 2026-08-04

CIK: 0000882095

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — gild-20260804.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (exhibit991earningspressrel.htm)

GRAPHIC — LOGO (gilead_transparentxlogoxsta.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: gild-20260804.htm · Sequence: 1

gild-20260804

0000882095false00008820952026-08-042026-08-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): August 4, 2026

GILEAD SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware 000-19731 94-3047598

(State or Other Jurisdiction of Incorporation) (Commission File No.) (IRS Employer Identification No.)

333 Lakeside Drive, Foster City, California

(Address of principal executive offices)

94404

(Zip Code)

650-574-3000

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered

Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition.

On August 4, 2026, Gilead Sciences, Inc., a Delaware corporation (“Gilead”), announced its financial results for the quarter ended June 30, 2026. A copy of the press release is filed as Exhibit 99.1 to this report.

Gilead has presented certain financial information in accordance with U.S. generally accepted accounting principles (“GAAP”) and also on a non-GAAP basis. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead’s operating results as reported under GAAP. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 10, 11, 12 and 13 of the press release filed as Exhibit 99.1 to this report.

The information in Item 2.02 and Item 9.01 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number Description

99.1

Press Release, issued by Gilead Sciences, Inc. on August 4, 2026

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GILEAD SCIENCES, INC.

(Registrant)

/s/ ANDREW D. DICKINSON

Andrew D. Dickinson

Chief Financial Officer

Date: August 4, 2026

Exhibit Index

Exhibit Number Description

99.1

Press Release, issued by Gilead Sciences, Inc. on August 4, 2026

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: exhibit991earningspressrel.htm · Sequence: 2

Document

GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS

Product Sales Excluding Veklury Increased 10% Year-Over-Year to $7.6 billion

Biktarvy Sales Increased 7% Year-Over-Year to $3.8 billion

Diluted Loss Per Share was $(8.45) and Non-GAAP Diluted Loss Per Share was $(6.75) Reflecting $(9.08) Per Share Acquired IPR&D and Tax Expenses Associated with Recent Acquisitions

Foster City, CA, August 4, 2026 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter 2026.

“Gilead delivered a very strong second quarter, with 10% year-over-year revenue growth in our base business driven by our HIV portfolio, Trodelvy and Livdelzi. HIV sales grew 12%, reflecting continued strength in treatment and the rapid expansion of our PrEP business, supporting an increase in our base business revenue expectations for 2026,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “We also made significant clinical progress with three FDA approvals and three positive Phase 3 updates. We look forward to delivering on our many opportunities in the second half of the year including another two potential launches in oncology and HIV.”

Second Quarter 2026 Financial Results

•Total second quarter 2026 revenues increased 10% to $7.8 billion compared to the same period in 2025, primarily driven by:

◦Higher sales of HIV products, Trodelvy® (sacituzumab govitecan-hziy) and Livdelzi® (seladelpar), partially offset by lower sales of Veklury® (remdesivir) as well as Cell Therapy and chronic hepatitis C virus (“HCV”) products; and

◦Higher royalty, contract and other revenues related to a previous sale of intellectual property.

•Diluted (loss) earnings per share (“EPS”) was $(8.45) in the second quarter 2026 compared to $1.56 in the same period in 2025. The decrease was primarily driven by the $(9.08) per share impact of acquired in-process research and development (“IPR&D”) expenses associated with our acquisitions of Arcellx, Inc. (“Arcellx”), Tubulis GmbH (“Tubulis”) and Ouro Medicines, LLC (“Ouro Medicines”), net of the impact of our collaboration with Lakefront Biotherapeutics NV (“Lakefront”) and the related taxes, as well as an IPR&D impairment related to assets previously acquired from Immunomedics, Inc. (“Immunomedics”) and higher operating expenses. The decrease was partially offset by higher revenues, lower income tax expense, and higher net gains from equity securities.

•Non-GAAP diluted (loss) EPS was $(6.75) in the second quarter 2026 compared to $2.01 in the same period in 2025. The decrease was primarily driven by the $(9.08) per share impact of acquired IPR&D and tax expenses discussed above, as well as higher non-GAAP selling, general and administrative (“SG&A”) expenses and non-GAAP income tax expense, partially offset by higher revenues.

•As of June 30, 2026, Gilead had $3.2 billion of cash, cash equivalents and marketable debt securities compared to $10.6 billion as of December 31, 2025. The decrease was primarily driven by year-to-date cash outflows of $11.3 billion related to acquisitions, $2.8 billion of debt repayments, $2.1 billion of dividend payments and $774 million of common stock repurchases, partially offset by $4.1 billion of net proceeds from debt financing and $6.1 billion of operating cash flow.

•During the second quarter 2026, Gilead generated $3.6 billion in operating cash flow.

•During the second quarter 2026, Gilead paid dividends of $1.0 billion and repurchased $355 million of common stock.

August 4, 2026

Second Quarter 2026 Product Sales

Total second quarter 2026 product sales increased 8% to $7.6 billion compared to the same period in 2025. Total second quarter 2026 product sales excluding Veklury increased 10% to $7.6 billion compared to the same period in 2025, primarily due to higher sales of HIV products, Trodelvy and Livdelzi, partially offset by lower sales of Cell Therapy and HCV products.

HIV product sales increased 12% to $5.7 billion in the second quarter 2026 compared to the same period in 2025, primarily driven by higher average realized price and demand.

•Biktarvy® (bictegravir 50mg/emtricitabine (“FTC”) 200mg/tenofovir alafenamide (“TAF”) 25mg) sales increased 7% to $3.8 billion in the second quarter 2026 compared to the same period in 2025, primarily driven by higher average realized price, favorable inventory dynamics and higher demand.

•Descovy® (FTC 200mg/TAF 25mg) sales increased 48% to $967 million in the second quarter 2026 compared to the same period in 2025, primarily driven by higher average realized price and demand.

The Liver Disease portfolio sales increased 10% to $877 million in the second quarter 2026 compared to the same period in 2025, primarily reflecting higher demand for Livdelzi, as well as chronic hepatitis B virus (“HBV”) products and Hepcludex® (bulevirtide-gmod), partially offset by lower sales for HCV products.

Veklury sales decreased 81% to $23 million in the second quarter 2026 compared to the same period in 2025, primarily driven by lower rates of COVID-19-related hospitalizations.

Cell Therapy product sales decreased 14% to $417 million in the second quarter 2026 compared to the same period in 2025, reflecting ongoing competitive headwinds.

•Yescarta® (axicabtagene ciloleucel) sales decreased 12% to $346 million in the second quarter 2026 compared to the same period in 2025, primarily driven by in- and out-of-class competition.

•Tecartus® (brexucabtagene autoleucel) sales decreased 24% to $70 million in the second quarter 2026 compared to the same period in 2025, primarily driven by in-class competition.

Trodelvy® (sacituzumab govitecan-hziy) sales increased 26% to $457 million in the second quarter 2026 compared to the same period in 2025, primarily driven by higher demand.

Second Quarter 2026 Product Gross Margin, Operating Expenses and Effective Tax Rate

•Product gross margin remained relatively flat at 79.3% in the second quarter 2026 compared to 78.7% in the same period in 2025. Non-GAAP product gross margin also remained flat at 86.9% in the second quarter 2026 compared to the same period in 2025.

•Research and development (“R&D”) expenses were $1.8 billion in the second quarter 2026 compared to $1.5 billion in the same period in 2025, primarily due to integration costs and other acquisition-related expenses, partially offset by lower oncology clinical study activity. Non-GAAP R&D expenses were $1.4 billion in the second quarter 2026 compared to $1.5 billion in the same period in 2025, primarily driven by lower oncology clinical study activity.

•Acquired IPR&D expenses were $11.2 billion in the second quarter 2026, primarily related to $7.0 billion for the Arcellx acquisition, $3.1 billion for the Tubulis acquisition and $1.0 billion for the Ouro Medicines acquisition, net of the impact of the Lakefront collaboration.

•SG&A expenses were $1.9 billion in the second quarter 2026 compared to $1.4 billion in the same period in 2025, primarily driven by integration costs related to the acquisitions and higher HIV promotional activities. Non-GAAP SG&A expenses were $1.5 billion in the second quarter 2026 compared to $1.4 billion in the same period in 2025, primarily due to higher HIV promotional activities.

August 4, 2026

•The effective tax rate (“ETR”) was (2.4)% in the second quarter 2026 compared to 19.3% in the same period in 2025. The non-GAAP ETR was (11.4)% in the second quarter 2026 compared to 18.8% in the same period in 2025. These changes primarily reflect the non-deductible acquired IPR&D expenses related to our acquisitions of Arcellx, Tubulis, and Ouro Medicines.

Guidance and Outlook

For the full year 2026, Gilead now expects:

(in millions, except per share amounts) August 4, 2026 Guidance

Low End High End Comparison to May 7, 2026 Guidance

Product sales $ 30,100 $ 30,400

Previously $30,000 to $30,400

Product sales excluding Veklury $ 29,800 $ 30,100

Previously $29,400 to $29,800

Veklury

~ $300

Previously ~ $600

Diluted loss per share $ (3.75) $ (3.40)

Previously $(3.25) to $(2.85)

Non-GAAP diluted loss per share $ (0.65) $ (0.30)

Previously $(1.05) to $(0.65)

Our full year 2026 GAAP and non-GAAP diluted loss per share guidance includes the impact of approximately $9.08 due to acquired IPR&D charges of $11.1 billion related to the Arcellx, Tubulis and Ouro Medicines transactions, net of the impact of the Lakefront collaboration and related taxes.

Additional information and a reconciliation between GAAP and non-GAAP financial information for the 2026 guidance is provided in the accompanying tables. The financial guidance is subject to a number of risks and uncertainties. See the Forward-Looking Statements section below.

Key Updates Since Our Last Quarterly Release

Virology

•Announced U.S. Food and Drug Administration (“FDA”) accepted a supplemental New Drug Application submission for Yeztugo® (lenacapavir) 300-mg tablets as a potential once-weekly oral formulation for HIV pre-exposure prophylaxis (“PrEP”), with a Prescription Drug User Fee Act target action date of February 2, 2027.

•Announced positive Phase 3 results from the ISLEND-1 and ISLEND-2 trials, in partnership with Merck, evaluating an investigational long-acting oral treatment regimen of islatravir 2 mg and lenacapavir 300 mg in adults with HIV who are virologically suppressed and switched from Biktarvy (ISLEND-1) or standard of care antiretroviral regimens (ISLEND-2) to the once-weekly combination.

•Received FDA accelerated approval for Hepcludex for the treatment of chronic hepatitis delta virus (“HDV”) infection in adults without cirrhosis or with compensated cirrhosis, which is now the first and only FDA-approved treatment for HDV in the U.S.

•Announced a donation of 2,000 vials of remdesivir to the Republic of Uganda to support response efforts to the current outbreak of Ebola Bundibugyo virus disease (“BVD”). Remdesivir is not approved for the treatment of Ebola virus disease, including BVD, anywhere globally, and the safety and efficacy of this use is not known.

Oncology

•Received FDA approval of Trodelvy for the first-line (“1L”) treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (“mTNBC”) as either a single agent for patients who are not candidates for PD-1/PD-L1 inhibitor-based therapy or in combination with Keytruda® (pembrolizumab) or Keytruda Qlex™ (pembrolizumab and berahyaluronidase alfa-pmph) for patients whose tumors express PD-L1 (CPS ≥10).

August 4, 2026

•Announced European Commission marketing authorization for Trodelvy as a monotherapy for the treatment of adult patients with unresectable locally advanced or mTNBC who have not received prior systemic therapy for metastatic disease and are not candidates for PD-1/PD-L1 inhibitor therapy.

•Received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for Trodelvy in combination with Keytruda® (pembrolizumab) for the treatment of adult patients with unresectable locally advanced or mTNBC who have not received prior systemic therapy for metastatic disease and whose tumors express PD-L1 (CPS≥10).

•Announced the discontinuation of the Phase 3 EVOKE-03 study, in partnership with Merck, evaluating Trodelvy in combination with Keytruda® for the investigational treatment of 1L metastatic non-small cell lung cancer with high PD-L1 expression (TPS ≥50%). The decision was based on the recommendation of the external Data Monitoring Committee, following review of data from a pre-specified final analysis of progression-free survival and interim analysis of overall survival.

•Presented new analyses at the 2026 American Society of Clinical Oncology meeting from the Phase 3 ASCENT-03 and ASCENT-04 studies evaluating Trodelvy with or without Keytruda® in 1L mTNBC, as well as new data on investigational anitocabtagene-autoleucel (“anito-cel”) clinical trial manufacturing experience in patients with newly diagnosed or relapsed/refractory multiple myeloma.

•Presented updated Phase 1 results for KITE-753, an investigational bicistronic autologous CD19/CD20 CAR T-cell therapy for relapsed or refractory B-cell lymphoma at the 2026 European Hematology Association meeting.

•Completed the acquisition of Tubulis for $3.15 billion in upfront consideration. This acquisition brings Gilead next-generation antibody-drug conjugate (“ADC”) assets, including GS-8824, a NaPi2b-directed topoisomerase-I inhibitor ADC, and a platform to develop novel ADCs.

Inflammation

•Completed the acquisition of Ouro Medicines for $1.675 billion in upfront consideration, which brings Gilead gamgertamig, an investigational clinical stage BCMAxCD3 T cell engager for autoimmune diseases. The acquisition was completed in collaboration with Lakefront, which equally shared the upfront payment and will equally share contingent milestone payments, subject to customary adjustments.

•Announced positive results from the Phase 3 IDEAL study, supporting the potential of Livdelzi to help people living with primary biliary cholangitis (“PBC”) with elevated alkaline phosphatase (“ALP”) levels (between 1.0 and 1.67xULN) whose disease remains inadequately controlled despite treatment with ursodeoxycholic acid (“UDCA”), or who are intolerant to UDCA.

•Presented data from the open-label Phase 3 ASSURE study at the 2026 European Association for the Study of the Liver Congress evaluating the long-term safety and tolerability profile of Livdelzi in people living with PBC with elevated ALP levels (between 1.0 and 1.67xULN) whose disease remains inadequately controlled despite treatment with UDCA, or who are intolerant to UDCA.

Corporate

•Issued $3.0 billion aggregate principal amount of senior unsecured notes and borrowed $1.1 billion aggregate principal amount under a one-year term loan facility.

•Announced a renewed 5-year collaboration with the World Health Organization to commit funding, strategic support and AmBisome donations toward eliminating visceral leishmaniasis.

•The Board declared a quarterly dividend of $0.82 per share of common stock for the third quarter of 2026. The dividend is payable on September 29, 2026, to stockholders of record at the close of business on September 15, 2026. Future dividends will be subject to Board approval.

Certain amounts and percentages in this press release may not sum or recalculate due to rounding.

August 4, 2026

Conference Call

At 1:30 p.m. Pacific Time today, Gilead will host a conference call to discuss Gilead’s results. A live webcast will be available on http://investors.gilead.com and will be archived on www.gilead.com for one year.

Non-GAAP Financial Information

The information presented in this document has been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), unless otherwise noted as non-GAAP. Management believes non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial information, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead’s operating results as reported under GAAP. Non-GAAP financial information generally excludes acquisition-related expenses including amortization of acquired intangible assets, restructuring charges and other items that are considered unusual or not representative of underlying trends of Gilead’s business, fair value adjustments of equity securities, the related tax charges or benefits associated with such exclusions and other discrete tax charges or benefits not representative of underlying trends such as changes in tax laws, transfers of intangible assets between certain legal entities, and effects of legal entity restructurings. Although Gilead consistently excludes the amortization of acquired intangible assets from the non-GAAP financial information, management believes that it is important for investors to understand that such intangible assets were recorded as part of acquisitions and contribute to ongoing revenue generation. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are provided in the accompanying tables.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Forward-Looking Statements

Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: Gilead’s ability to achieve its full year 2026 financial guidance, including as a result of the uncertainty of the amount and timing of Veklury revenues, the impact from Medicare Part D pricing reform in the Inflation Reduction Act, the expiration of subsidies related to the Affordable Care Act, our most-favored-nation pricing agreement with the U.S. government, changes in U.S. regulatory or legislative policies, and changes in U.S. trade policies, including tariffs; Gilead’s ability to make progress on any of its long-term ambitions or priorities laid out in its corporate strategy; Gilead’s ability to accelerate or sustain revenues for its virology, oncology, inflammation and other programs; Gilead’s ability to realize the potential benefits of acquisitions, collaborations or licensing arrangements, including the arrangements with Arcellx, Immunomedics, Lakefront, Merck, Ouro Medicines, The World Health Organization and Tubulis; the risk that Gilead’s U.S. manufacturing and R&D investment may not achieve their intended benefits; patent protection and estimated loss of exclusivity for our products and product candidates; Gilead’s ability to initiate, progress or complete clinical trials within currently anticipated timeframes or at all, the possibility of unfavorable results from ongoing and additional clinical trials, including those involving Livdelzi, Trodelvy, anito-cel, KITE-753 and lenacapavir (such as ASCENT-03, ASCENT-04, ASSURE, IDEAL, ISLEND-1 and ISLEND-2), and the risk that safety and efficacy data from clinical trials may not warrant further development of Gilead’s product candidates or the product candidates of Gilead’s strategic partners; Gilead’s ability to resolve the issues cited by the FDA in pending clinical holds to the satisfaction of the FDA and the risk that FDA may not remove such clinical holds, in whole or in part, in a timely manner or at

August 4, 2026

all; Gilead’s ability to submit new drug applications for new product candidates or expanded indications in the currently anticipated timelines; Gilead’s ability to receive or maintain regulatory approvals in a timely manner or at all, and the risk that any such approvals, if granted, may be subject to significant limitations on use and may be subject to withdrawal or other adverse actions by the applicable regulatory authority, including those involving Hepcludex, Trodelvy and once-weekly oral Yeztugo; Gilead’s ability to successfully commercialize its products; the risk of potential disruptions to the manufacturing and supply chain of Gilead’s products; pricing and reimbursement pressures from government agencies and other third parties, including required rebates and other discounts; a larger than anticipated shift in payer mix to more highly discounted payer segments; market share and price erosion caused by the introduction of generic versions of Gilead products; the risk that physicians and patients may not see advantages of Gilead’s products over other therapies, including Hepcludex and Trodelvy; Gilead’s ability to effectively manage the access strategy relating to lenacapavir for HIV PrEP, subject to necessary regulatory approvals; and other risks identified from time to time in Gilead’s reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ significantly from these estimates. Further, results for the quarter ended June 30, 2026 are not necessarily indicative of operating results for any future periods. Gilead directs readers to its press releases, annual reports on Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.

The reader is cautioned that forward-looking statements are not guarantees of future performance and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update or supplement any such forward-looking statements other than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements.

Additional information is available on our Investor Relations website, https://investors.gilead.com. Among other things, an estimate of Acquired IPR&D expenses is expected to be made available on the Quarterly Results page within the first ten (10) days after the end of each quarter.

# # #

Gilead owns or has rights to various trademarks, copyrights and trade names used in its business, including the following: GILEAD®, GILEAD SCIENCES®, KITE®, AMBISOME®, ATRIPLA®, BIKTARVY®, CAYSTON®, COMPLERA®, DESCOVY®, DESCOVY FOR PREP®, EMTRIVA®, EPCLUSA®, EVIPLERA®, GENVOYA®, HARVONI®, HEPCLUDEX®, JYSELECA®, LIVDELZI®/LYVDELZI®, LETAIRIS®, ODEFSEY®, SOVALDI®, STRIBILD®, SUNLENCA®, TECARTUS®, TRODELVY®, TRUVADA®, TRUVADA FOR PREP®, TYBOST®, VEKLURY®, VEMLIDY®, VIREAD®, VOSEVI®, YESCARTA®, YEZTUGO®/YEYTUO® and ZYDELIG®. Other trademarks and trade names are the property of their respective owners.

For more information on Gilead Sciences, Inc., please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

CONTACTS: Investors: Jacquie Ross, CFA investor_relations@gilead.com

Media: Ashleigh Koss public_affairs@gilead.com

August 4, 2026

GILEAD SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

Three Months Ended Six Months Ended

June 30, June 30,

(in millions, except per share amounts) 2026 2025 2026 2025

Revenues:

Product sales $ 7,627 $ 7,054 $ 14,574 $ 13,668

Royalty, contract and other revenues 176 27 189 81

Total revenues 7,803 7,082 14,763 13,749

Costs and expenses:

Cost of goods sold 1,579 1,501 3,023 3,041

Research and development expenses 1,764 1,491 3,136 2,870

Acquired in-process research and development expenses 11,183 61 11,290 315

In-process research and development impairments 1,750 190 1,750 190

Selling, general and administrative expenses 1,921 1,365 3,372 2,623

Total costs and expenses 18,197 4,608 22,571 9,038

Operating (loss) income (10,394) 2,474 (7,808) 4,711

Interest expense 247 254 487 513

Other (income) expense, net (387) (208) (621) 120

(Loss) income before income taxes (10,254) 2,429 (7,674) 4,077

Income tax expense 242 468 801 802

Net (loss) income $ (10,496) $ 1,960 $ (8,475) $ 3,275

Basic (loss) earnings per share $ (8.45) $ 1.57 $ (6.82) $ 2.63

Diluted (loss) earnings per share $ (8.45) $ 1.56 $ (6.82) $ 2.61

Shares used in basic (loss) earnings per share calculation 1,243 1,245 1,243 1,246

Shares used in diluted (loss) earnings per share calculation 1,243 1,255 1,243 1,257

Supplemental Information:

Cash dividends declared per share $ 0.82 $ 0.79 $ 1.64 $ 1.58

Product gross margin 79.3 % 78.7 % 79.3 % 77.7 %

Research and development expenses as a % of revenues 22.6 % 21.1 % 21.2 % 20.9 %

Selling, general and administrative expenses as a % of revenues 24.6 % 19.3 % 22.8 % 19.1 %

Operating margin (133.2) % 34.9 % (52.9) % 34.3 %

Effective tax rate (2.4) % 19.3 % (10.4) % 19.7 %

August 4, 2026

GILEAD SCIENCES, INC.

TOTAL REVENUE SUMMARY

(unaudited)

Three Months Ended Six Months Ended

June 30, June 30,

(in millions, except percentages) 2026 2025 Change 2026 2025 Change

Product sales:

HIV $ 5,693 $ 5,088 12% $ 10,723 $ 9,675 11%

Liver Disease

877 795 10% 1,644 1,553 6%

Oncology 873 849 3% 1,683 1,606 5%

Other 161 202 (20)% 357 410 (13)%

Total product sales excluding Veklury 7,604 6,934 10% 14,406 13,245 9%

Veklury 23 121 (81)% 167 423 (60)%

Total product sales 7,627 7,054 8% 14,574 13,668 7%

Royalty, contract and other revenues 176 27 NM 189 81 NM

Total revenues $ 7,803 $ 7,082 10% $ 14,763 $ 13,749 7%

________________________________

NM - Not Meaningful

August 4, 2026

GILEAD SCIENCES, INC.

NON-GAAP FINANCIAL INFORMATION(1)

(unaudited)

Three Months Ended Six Months Ended

June 30, June 30,

(in millions, except percentages) 2026 2025 Change 2026 2025 Change

Non-GAAP:

Cost of goods sold $ 999 $ 922 8% $ 1,868 $ 1,883 (1)%

Research and development expenses $ 1,429 $ 1,450 (1)% $ 2,783 $ 2,789 —%

Acquired IPR&D expenses $ 11,183 $ 61 NM $ 11,290 $ 315 NM

Selling, general and administrative expenses $ 1,521 $ 1,358 12% $ 2,884 $ 2,580 12%

Other (income) expense, net $ (44) $ (66) (33)% $ (137) $ (164) (17)%

Diluted (loss) earnings per share $ (6.75) $ 2.01 NM $ (4.70) $ 3.82 NM

Shares used in non-GAAP diluted (loss) earnings per share calculation 1,243 1,255 (1)% 1,243 1,257 (1)%

Product gross margin 86.9 % 86.9 % -3 bps 87.2 % 86.2 % 96 bps

Research and development expenses as a % of revenues 18.3 % 20.5 % -217 bps 18.9 % 20.3 % -143 bps

Selling, general and administrative expenses as a % of revenues 19.5 % 19.2 % 32 bps 19.5 % 18.8 % 77 bps

Operating margin (93.9) % 46.5 % NM (27.5) % 45.0 % NM

Effective tax rate (11.4) % 18.8 % NM (32.4) % 17.6 % NM

________________________________

NM - Not Meaningful

(1) Refer to Non-GAAP Financial Information section above for further disclosures on non-GAAP financial measures. A reconciliation between GAAP and non-GAAP financial information is provided in the tables below.

August 4, 2026

GILEAD SCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION

(unaudited)

Three Months Ended Six Months Ended

June 30, June 30,

(in millions, except percentages and per share amounts) 2026 2025 2026 2025

Cost of goods sold reconciliation:

GAAP cost of goods sold $ 1,579 $ 1,501 $ 3,023 $ 3,041

Acquisition-related – amortization(1)

(579) (579) (1,155) (1,158)

Restructuring — — (1) —

Non-GAAP cost of goods sold $ 999 $ 922 $ 1,868 $ 1,883

Product gross margin reconciliation:

GAAP product gross margin 79.3 % 78.7 % 79.3 % 77.7 %

Acquisition-related – amortization(1)

7.6 % 8.2 % 7.9 % 8.5 %

Restructuring — % — % — % — %

Non-GAAP product gross margin 86.9 % 86.9 % 87.2 % 86.2 %

Research and development expenses reconciliation:

GAAP research and development expenses $ 1,764 $ 1,491 $ 3,136 $ 2,870

Acquisition-related – other costs(2)

(333) (35) (336) (37)

Restructuring (2) (6) (17) (44)

Non-GAAP research and development expenses $ 1,429 $ 1,450 $ 2,783 $ 2,789

IPR&D impairment reconciliation:

GAAP IPR&D impairment $ 1,750 $ 190 $ 1,750 $ 190

IPR&D impairment (1,750) (190) (1,750) (190)

Non-GAAP IPR&D impairment $ — $ — $ — $ —

Selling, general and administrative expenses reconciliation:

GAAP selling, general and administrative expenses $ 1,921 $ 1,365 $ 3,372 $ 2,623

Acquisition-related – other costs(2)

(385) — (385) —

Restructuring (15) (7) (40) (43)

Other(3)

— — (63) —

Non-GAAP selling, general and administrative expenses $ 1,521 $ 1,358 $ 2,884 $ 2,580

Operating (loss) income reconciliation:

GAAP operating (loss) income $ (10,394) $ 2,474 $ (7,808) $ 4,711

Acquisition-related – amortization(1)

579 579 1,155 1,158

Acquisition-related – other costs(2)

718 35 721 37

Restructuring 17 13 57 88

IPR&D impairment 1,750 190 1,750 190

Other(3)

— — 63 —

Non-GAAP operating (loss) income $ (7,329) $ 3,290 $ (4,062) $ 6,183

Operating margin reconciliation:

GAAP operating margin (133.2) % 34.9 % (52.9) % 34.3 %

Acquisition-related – amortization(1)

7.4 % 8.2 % 7.8 % 8.4 %

Acquisition-related – other costs(2)

9.2 % 0.5 % 4.9 % 0.3 %

Restructuring 0.2 % 0.2 % 0.4 % 0.6 %

IPR&D impairment 22.4 % 2.7 % 11.9 % 1.4 %

Other(3)

— % — % 0.4 % — %

Non-GAAP operating margin (93.9) % 46.5 % (27.5) % 45.0 %

Other (income) expense, net reconciliation:

GAAP other (income) expense, net $ (387) $ (208) $ (621) $ 120

Gain (loss) from equity securities, net 343 142 485 (284)

Non-GAAP other (income) expense, net $ (44) $ (66) $ (137) $ (164)

August 4, 2026

GILEAD SCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued)

(unaudited)

Three Months Ended Six Months Ended

June 30, June 30,

(in millions, except percentages and per share amounts) 2026 2025 2026 2025

(Loss) income before income taxes reconciliation:

GAAP (loss) income before income taxes $ (10,254) $ 2,429 $ (7,674) $ 4,077

Acquisition-related – amortization(1)

579 579 1,155 1,158

Acquisition-related – other costs(2)

718 35 721 37

Restructuring 17 13 57 88

IPR&D impairment 1,750 190 1,750 190

(Gain) loss from equity securities, net (343) (142) (485) 284

Other(3)

— — 63 —

Non-GAAP (loss) income before income taxes $ (7,531) $ 3,103 $ (4,412) $ 5,834

Income tax expense reconciliation:

GAAP income tax expense $ 242 $ 468 $ 801 $ 802

Income tax effect of non-GAAP adjustments:

Acquisition-related – amortization(1)

119 120 236 241

Acquisition-related – other costs(2)

79 — 79 —

Restructuring 3 2 9 15

IPR&D impairment 415 51 415 51

(Gain) loss from equity securities, net (42) (11) (108) 10

Discrete and related tax charges(4)

44 (48) (2) (90)

Non-GAAP income tax expense $ 860 $ 583 $ 1,430 $ 1,029

Effective tax rate reconciliation:

GAAP effective tax rate (2.4) % 19.3 % (10.4) % 19.7 %

Income tax effect of above non-GAAP adjustments and discrete and related tax adjustments(4)

(9.1) % (0.5) % (22.0) % (2.0) %

Non-GAAP effective tax rate (11.4) % 18.8 % (32.4) % 17.6 %

Net (loss) income reconciliation:

GAAP net (loss) income $ (10,496) $ 1,960 $ (8,475) $ 3,275

Acquisition-related – amortization(1)

461 459 919 917

Acquisition-related – other costs(2)

640 35 642 37

Restructuring 14 11 48 72

IPR&D impairment 1,335 139 1,335 139

(Gain) loss from equity securities, net (301) (131) (377) 275

Discrete and related tax charges(4)

(44) 48 2 90

Other(3)

— — 63 —

Non-GAAP net (loss) income $ (8,391) $ 2,521 $ (5,842) $ 4,806

Diluted (loss) earnings per share reconciliation:

GAAP diluted (loss) earnings per share $ (8.45) $ 1.56 $ (6.82) $ 2.61

Acquisition-related – amortization(1)

0.37 0.37 0.74 0.73

Acquisition-related – other costs(2)

0.51 0.03 0.52 0.03

Restructuring 0.01 0.01 0.04 0.06

IPR&D impairment 1.07 0.11 1.07 0.11

(Gain) loss from equity securities, net (0.24) (0.10) (0.30) 0.22

Discrete and related tax charges(4)

(0.04) 0.04 — 0.07

Other(3)

— — 0.05 —

Non-GAAP diluted (loss) earnings per share $ (6.75) $ 2.01 $ (4.70) $ 3.82

August 4, 2026

GILEAD SCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued)

(unaudited)

Three Months Ended Six Months Ended

June 30, June 30,

(in millions, except percentages and per share amounts) 2026 2025 2026 2025

Non-GAAP adjustment summary:

Cost of goods sold adjustments $ 579 $ 579 $ 1,156 $ 1,158

Research and development expenses adjustments 335 41 352 81

IPR&D impairment adjustments 1,750 190 1,750 190

Selling, general and administrative expenses adjustments 400 7 488 43

Total non-GAAP adjustments to costs and expenses

3,065 817 3,746 1,472

Other (income) expense, net, adjustments (343) (142) (485) 284

Total non-GAAP adjustments before income taxes 2,722 675 3,262 1,757

Income tax effect of non-GAAP adjustments above (574) (162) (631) (316)

Discrete and related tax charges(4)

(44) 48 2 90

Total non-GAAP adjustments to net income $ 2,105 $ 560 $ 2,633 $ 1,530

________________________________

(1) Relates to amortization of acquired intangibles.

(2) Adjustments include integration expenses and contingent consideration fair value adjustments associated with Gilead’s recent acquisitions.

(3) Adjustments include donations of equity securities to the Gilead Foundation, a California nonprofit organization, during the first quarter of 2026.

(4) Represents discrete and related deferred tax charges or benefits primarily associated with acquisition-related adjustments and transfers of intangible assets from a foreign subsidiary to Ireland and the United States.

August 4, 2026

GILEAD SCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP 2026 FULL-YEAR GUIDANCE(1)

(unaudited)

(in millions, except percentages and per share amounts) Provided February 10, 2026 Updated May 7, 2026 Updated August 4, 2026

Projected product gross margin GAAP to non-GAAP reconciliation:

GAAP projected product gross margin ~ 79.0% ~ 79.0% ~ 79.0%

Acquisition-related expenses ~ 8.0% ~ 8.0% ~ 8.0%

Non-GAAP projected product gross margin ~ 87.0% ~ 87.0% ~ 87.0%

Projected operating income (loss) GAAP to non-GAAP reconciliation:

GAAP projected operating income (loss) $11,400 - $11,900 $(1,000) - $(500) $(2,250) - $(1,850)

Acquisition-related, IPR&D impairment, restructuring and other expenses ~ 2,400 ~ 3,400 ~ 5,150

Non-GAAP projected operating income $13,800 - $14,300 $2,400 - $2,900 $2,900 - $3,300

Projected effective tax rate GAAP to non-GAAP reconciliation:(2)

GAAP projected effective tax rate ~ 21% ~ (150%) - (220%) ~ (80%) - (90%)

Income tax effect of above non-GAAP adjustments and fair value adjustments of equity securities, and discrete and related tax adjustments (~ 1%) NM NM

Non-GAAP projected effective tax rate ~ 20% ~ 190% - 140% ~ 140% - 115%

Projected diluted earnings (loss) per share GAAP to non-GAAP reconciliation:

GAAP projected diluted earnings (loss) per share $6.75 - $7.15 $(3.25) - $(2.85) $(3.75) - $(3.40)

Acquisition-related, IPR&D impairment, restructuring and other expenses, fair value adjustments of equity securities and discrete and related tax adjustments ~ 1.70 ~ 2.20 ~ 3.10

Non-GAAP projected diluted earnings (loss) per share $8.45 - $8.85 $(1.05) - $(0.65) $(0.65) - $(0.30)

________________________________

NM - Not Meaningful

(1) Our full-year guidance excludes the potential impact of any (i) acquisitions or business development transactions that have not been executed, (ii) future fair value adjustments of equity securities and (iii) discrete tax charges or benefits associated with changes in tax related laws and guidelines that have not been enacted, as Gilead is unable to project such amounts. The non-GAAP full-year guidance includes non-GAAP adjustments to actual current period results as well as adjustments for the known future impact associated with events that have already occurred, such as future amortization of our intangible assets and the future impact of discrete and related deferred tax charges or benefits primarily associated with transfers of intangible assets from a foreign subsidiary to Ireland and the United States.

(2) The GAAP and non-GAAP projected effective tax rates for the August 4, 2026 update include the impact of Acquired IPR&D expenses related to the acquisitions of Arcellx, Tubulis and Ouro Medicines, which are not deductible for tax purposes. Without these Acquired IPR&D expenses, the GAAP and non-GAAP projected effective tax rate for FY26 would be ~21% and ~20%, respectively.

August 4, 2026

GILEAD SCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

June 30, December 31,

(in millions) 2026 2025

Assets

Cash, cash equivalents and marketable debt securities $ 3,179 $ 10,605

Accounts receivable, net 5,055 4,913

Inventories(1)

4,298 4,368

Property, plant and equipment, net 5,833 5,606

Intangible assets, net 14,032 16,978

Goodwill 8,314 8,314

Other assets 8,652 8,239

Total assets $ 49,362 $ 59,023

Liabilities and Stockholders’ Equity

Current liabilities $ 11,020 $ 11,813

Long-term liabilities 26,598 24,592

Stockholders’ equity(2)

11,744 22,618

Total liabilities and stockholders’ equity $ 49,362 $ 59,023

________________________________

(1) Includes current and long-term inventories, which are disclosed separately in the notes to our financial statements in Form 10-K and Form 10-Q.

(2) As of June 30, 2026 and December 31, 2025, there were 1,241 shares of common stock issued and outstanding.

August 4, 2026

GILEAD SCIENCES, INC.

SELECTED CASH FLOW INFORMATION

(unaudited)

Three Months Ended Six Months Ended

June 30, June 30,

(in millions) 2026 2025 2026 2025

Net cash provided by operating activities $ 3,573 $ 827 $ 6,117 $ 2,584

Net cash used in investing activities (10,347) (2,116) (8,577) (2,531)

Net cash provided by (used in) financing activities 2,344 (1,566) (1,895) (4,993)

Effect of exchange rate changes on cash and cash equivalents (19) 73 (30) 92

Net change in cash and cash equivalents (4,450) (2,782) (4,385) (4,848)

Cash and cash equivalents at beginning of period 7,628 7,926 7,564 9,991

Cash and cash equivalents at end of period $ 3,179 $ 5,144 $ 3,179 $ 5,144

Three Months Ended Six Months Ended

June 30, June 30,

(in millions) 2026 2025 2026 2025

Net cash provided by operating activities $ 3,573 $ 827 $ 6,117 $ 2,584

Purchases of property, plant and equipment (140) (107) (257) (211)

Free cash flow(1)

$ 3,432 $ 720 $ 5,859 $ 2,373

________________________________

(1) Free cash flow is a non-GAAP liquidity measure. Please refer to our disclosures in the Non-GAAP Financial Information section above.

August 4, 2026

GILEAD SCIENCES, INC.

PRODUCT SALES SUMMARY

(unaudited)

Three Months Ended Six Months Ended

June 30, June 30,

(in millions) 2026 2025 2026 2025

HIV

Biktarvy U.S. $ 2,981 $ 2,799 $ 5,553 $ 5,272

Europe 468 429 905 804

Rest of World 323 302 675 603

3,772 3,530 7,133 6,679

Descovy U.S. 921 601 1,682 1,139

Europe 23 24 46 45

Rest of World 23 28 46 55

967 653 1,774 1,239

Genvoya U.S. 236 322 451 627

Europe 37 40 70 79

Rest of World 16 16 32 35

289 377 553 741

Odefsey U.S. 171 221 324 436

Europe 58 66 117 123

Rest of World 10 11 19 20

239 298 461 579

Symtuza - Revenue share(1)

U.S. 105 88 211 170

Europe 30 33 59 62

Rest of World 3 3 5 6

138 124 275 238

Yeztugo U.S. 223 15 382 15

Europe — — — —

Rest of World 9 — 16 —

232 15 397 15

Other HIV(2)

U.S. 23 50 59 101

Europe 24 33 51 63

Rest of World 10 9 19 19

56 92 129 183

Total HIV U.S. 4,659 4,096 8,663 7,760

Europe 640 624 1,248 1,177

Rest of World 393 368 812 738

5,693 5,088 10,723 9,675

August 4, 2026

GILEAD SCIENCES, INC.

PRODUCT SALES SUMMARY - (Continued)

(unaudited)

Three Months Ended Six Months Ended

June 30, June 30,

(in millions) 2026 2025 2026 2025

Liver Disease

Livdelzi U.S. 147 74 261 114

Europe 20 4 39 4

Rest of World — — — —

167 78 300 118

Sofosbuvir / Velpatasvir(3)

U.S. 142 184 283 351

Europe 81 81 141 161

Rest of World 80 76 162 175

303 342 586 687

Vemlidy U.S. 124 122 215 222

Europe 13 13 27 24

Rest of World 152 117 284 257

289 252 526 504

Other Liver Disease(4)

U.S. 20 33 35 61

Europe 79 72 157 148

Rest of World 19 19 40 35

118 123 232 244

Total Liver Disease U.S. 433 413 795 748

Europe 193 170 363 338

Rest of World 251 211 486 467

877 795 1,644 1,553

Veklury

Veklury U.S. 14 51 126 250

Europe 2 19 17 41

Rest of World 7 50 25 132

23 121 167 423

Oncology

Cell Therapy

Tecartus U.S. 29 41 59 82

Europe 34 41 71 72

Rest of World 8 9 16 17

70 92 146 171

Yescarta U.S. 132 162 252 321

Europe 139 154 285 304

Rest of World 75 77 142 154

346 393 679 779

Total Cell Therapy U.S. 161 203 311 403

Europe 173 196 356 376

Rest of World 83 86 157 171

417 485 824 949

Trodelvy

Trodelvy U.S. 307 224 560 405

Europe 92 96 187 171

Rest of World 57 44 112 81

457 364 859 657

Total Oncology U.S. 468 427 871 808

Europe 265 291 543 547

Rest of World 140 131 269 252

873 849 1,683 1,606

August 4, 2026

GILEAD SCIENCES, INC.

PRODUCT SALES SUMMARY - (Continued)

(unaudited)

Three Months Ended Six Months Ended

June 30, June 30,

(in millions) 2026 2025 2026 2025

Other

AmBisome U.S. 4 7 11 13

Europe 47 65 106 132

Rest of World 59 56 131 123

110 129 248 268

Other(5)

U.S. 22 44 61 91

Europe 8 8 16 16

Rest of World 21 21 32 35

51 73 109 143

Total Other U.S. 26 52 72 104

Europe 55 73 122 149

Rest of World 80 77 163 158

161 202 357 410

Total product sales U.S. 5,601 5,038 10,527 9,669

Europe 1,155 1,178 2,292 2,251

Rest of World 872 838 1,755 1,747

$ 7,627 $ 7,054 $ 14,574 $ 13,668

________________________________

(1) Represents Gilead’s revenue from cobicistat (“C”), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.

(2) Includes Atripla, Complera/Eviplera, Emtriva, Stribild, Sunlenca, Truvada and Tybost.

(3) Includes Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”).

(4) Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Sovaldi, Viread and Vosevi.

(5) Includes Cayston, Jyseleca, Letairis and Zydelig.

GRAPHIC — LOGO

GRAPHIC

Filename: gilead_transparentxlogoxsta.jpg · Sequence: 6

Binary file (36697 bytes)

Download gilead_transparentxlogoxsta.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover Cover

Aug. 04, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

Aug. 04, 2026

Entity Registrant Name

GILEAD SCIENCES, INC.

Entity Incorporation, State or Country Code

Entity File Number

000-19731

Entity Tax Identification Number

94-3047598

Entity Address, Address Line One

333 Lakeside Drive

Entity Address, City or Town

Foster City

Entity Address, State or Province

Entity Address, Postal Zip Code

94404

City Area Code

650

Local Phone Number

574-3000

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value, $0.001 per share

Trading Symbol

GILD

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Entity Central Index Key

0000882095

Amendment Flag

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration